^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    fludarabine IV

    i
    Other names: NSC 312887, NSC-312887, NSC312887
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    2d
    Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders (clinicaltrials.gov)
    P2, N=48, Recruiting, Masonic Cancer Center, University of Minnesota | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Rituxan (rituximab) • cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • busulfan
    2d
    KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, Corregene Biotechnology Co., Ltd | Not yet recruiting --> Active, not recruiting | N=18 --> 8
    Enrollment closed • Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12
    |
    cyclophosphamide • fludarabine IV
    2d
    Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, Patrick C. Johnson, MD | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    cyclophosphamide • Calquence (acalabrutinib) • Breyanzi (lisocabtagene maraleucel) • fludarabine IV
    2d
    NCI-2020-01626: Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis (clinicaltrials.gov)
    P2, N=79, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | N=60 --> 79 | Trial completion date: Dec 2029 --> Apr 2030
    Enrollment closed • Enrollment change • Trial completion date
    |
    Jakafi (ruxolitinib) • cyclophosphamide • methotrexate • melphalan • fludarabine IV • busulfan
    3d
    A prospective, multiple centers, single arm clinical study on the efficacy and safety of decitabine combined with improved TBF conditioning regimen in patients with myelodysplastic syndrome accompanied by myelofibrosis received Allogeneic hematopoietic stem cell transplantation. (ChiCTR2500114465)
    P2, N=54, Not yet recruiting, The First Affiliated Hospital of Zhejiang University, School of Medicine,; The First Affiliated Hospital of Zhejiang University, School of Medicine,
    New P2 trial
    |
    decitabine • fludarabine IV • thiotepa • busulfan
    3d
    Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=15, Completed, National Heart, Lung, and Blood Institute (NHLBI) | Active, not recruiting --> Completed
    Trial completion
    |
    TP53 (Tumor protein P53) • SF3B1 (Splicing Factor 3b Subunit 1)
    |
    TP53 mutation • SF3B1 mutation
    |
    Keytruda (pembrolizumab) • Imbruvica (ibrutinib) • fludarabine IV
    4d
    GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2029 --> Sep 2033
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PGR (Progesterone receptor) • GPNMB (Glycoprotein Nmb)
    |
    PD-L1 expression • HER-2 negative
    |
    cyclophosphamide • fludarabine IV
    5d
    GRACE: GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, University of Manchester
    New P1/2 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    cyclophosphamide • fludarabine IV
    5d
    Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=70 --> 33 | Trial completion date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2026 --> Jun 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    cyclophosphamide • fludarabine IV
    5d
    IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy (clinicaltrials.gov)
    P1, N=3, Terminated, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | N=36 --> 3 | Trial completion date: Oct 2026 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> Oct 2025; The collaborating party has adjusted its R&D strategy and terminated the study.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    6d
    AML16: A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=206, Active, not recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Jun 2025 --> Sep 2025
    Trial primary completion date
    |
    sorafenib • azacitidine • etoposide IV • decitabine • daunorubicin • idarubicin hydrochloride • mitoxantrone • fludarabine IV • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Neupogen (filgrastim) • dexrazoxane
    6d
    Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation (clinicaltrials.gov)
    P2, N=43, Completed, Medical College of Wisconsin | Active, not recruiting --> Completed
    Trial completion
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    fludarabine IV • captisol-enabled melphalan